Drug intelligence / Profile preview

h5n1 whole virus influenza vaccine

Development stage
Unknown
Lead developer
GSK
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

The **H5N1 whole virus influenza vaccine** is an inactivated or killed vaccine derived from the entire H5N1 (avian/bird flu) influenza virus. Unlike subunit or split-virus vaccines, it contains the complete virion, ensuring presentation of all viral antigens to the immune system. This vaccine is designed for active immunization against influenza A virus H5N1 subtype, which poses a pandemic threat due to its potential for high mortality and limited human immunity[6]. Whole virus vaccines typically induce robust antibody and T-cell responses owing to their antigenic breadth. They are produced by culturing the virus (often in eggs or cell lines), followed by inactivation; the resultant vaccine may include an adjuvant to enhance immune response. These vaccines are intended primarily for pandemic preparedness and stockpiling rather than routine commercial availability[4][6]. They may be deployed if H5N1 strains gain capability for efficient human-to-human transmission or during an outbreak among high-risk populations[6].

Other names
h5n1 whole virus influenza vaccineh-5n1 whole virus influenza vaccineh 5n1 whole virus influenza vaccinewhole virion h5n1 vaccinewhole virus h5n1 influenza vaccineinactivated whole virus h5n1 vaccine
02

Targets

NeuraminidaseHA (Hemagglutinin)

Beyond the preview

Go deeper on h5n1 whole virus influenza vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on h5n1 whole virus influenza vaccine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call